Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc REPCF


Primary Symbol: V.RP

Technology Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Replicel Life Sciences Inc > The Plan
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(19)
•••
Comment by RPINVESTOR1on Mar 21, 2024 12:33pm
85 Views
Post# 35945270

RE:RE:RE:RE:RE:The Plan

RE:RE:RE:RE:RE:The PlanHi Ingiboy:-

My answers to your questions are 1. Most likely, and 2. Yes.

After thinking about this relationship yesterday, I decided to send a second e-mail to the British Columbia Securities Commisssion asking them to add MainPointe Pharmaceuticals to the list of insiders who potentially could benefit from a 'yes' vote on the Offer to Purchase and who should not be allowed to participate in the vote.

Also, my letter to Larissa Huang of YOFOTO China has gone unanswered. I can understand that she may not want to get publicly involved in this issue. I have to believe that she left the Board of Directors suddenly in 2019 because she realized that she had been fooled by the representations of the former CEO of Replicel.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities